SCHEMBL30784206

SCHEMBL30784206

Nc1c(Br)cc(Cl)cc1C(=O)NC1CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
HPGD P15428 3/20 0.48
KDM4E B2RXH2 1/20 0.47
GLA P06280 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
ESR2 Q92731 1/20 0.47
P2RX7 Q99572 1/20 0.44
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
NPC1 O15118 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA3 P07451 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA5A P35218 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27779125 0.82 ALDH1A1 (0.48) ALDH1A1HPGDKDM4EGLAPOLB
SCHEMBL30783917 0.82 KMT2A (0.50) ALDH1A1HPGDKDM4EMEN1CYP1A2
SCHEMBL28451133 0.79 ALDH1A1 (0.46) ALDH1A1HPGDPOLBP2RX7MEN1
SCHEMBL28522500 0.79 CYP1A2 (0.53) HPGDMEN1CYP1A2CYP2C19KMT2A
SCHEMBL28522503 0.79 CYP1A2 (0.53) HPGDMEN1CYP1A2CYP2C19KMT2A
SCHEMBL590875 0.78 CACNA1I (0.44) ALDH1A1POLBNPC1RAB9AHTR4
SCHEMBL28001258 0.78 MEN1 (0.56) ALDH1A1HPGDKDM4EMEN1CYP1A2
SCHEMBL25363319 0.78 WDR5 (0.41) ALDH1A1KDM4EGLAGAAKMT2A
SCHEMBL30784312 0.77 CYP1A2 (0.55) ALDH1A1HPGDGLAMEN1CYP1A2
SCHEMBL31330617 0.77 RAB9A (0.49) ALDH1A1HPGDKDM4EGAAP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024026424-A1 QUINAZOLINONE DERIVATIVES AS AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed